Previous 10 | Next 10 |
Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022 Reinforces and Diversifies FIRDAPSE Long-Term Patent Portfolio Patent Portfolio Provides Intellectual Property Protection Until 2034 CORAL G...
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders Together, Will Ring the Nasdaq Opening Bell to Kick-Off Rare Disease Day on February 28, 2022 CORAL GABLES, Fla., Feb. 24,...
CORAL GABLES, Fla., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on developing and commercializing novel high-quality medicines for patients living with rare diseases, today ...
Although home run stocks, or equities capable of producing life-altering returns in a short period of time, are far from commonplace, the biopharmaceutical industry has been fertile ground for explosive growth vehicles for a number of years now. The core reason is the industry's ongoing inn...
Gainers: Haemonetics (NYSE:HAE) +13%. Second Sight Medical Products (NASDAQ:EYES) +8%. Catalyst Pharmaceuticals (NASDAQ:CPRX) +6%. Quotient (NASDAQ:QTNT) +5%. Ocuphire Pharma (NASDAQ:OCUP) +3%. Losers: Pulse Biosciences (NASDAQ:PLSE) -36%. Karyopharm Th...
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported preliminary Q4 revenue estimates and 2022 outlook. Q4 2021 total revenues expected to increase ~24% Y/Y to ~$38M. Consensus Revenue Estimate for Q4 is $36.90M. Full year 2021 total revenues expected to rise by 18% Y/Y to ~$141M. Consen...
2021 Total Revenues Estimated at $141 Million, Representing 18% YoY Growth Forecast 2022 Total Revenues of Between $195 Million and $205 Million, Representing YoY Growth of 38% to 45% Recently Regained Orphan Drug Exclusivity in the U.S. for Amifampridine to Treat LEMS ...
Catalyst Pharmaceuticals (CPRX -0.7%) said a District Court entered summary judgment in favor of the company in a lawsuit against the FDA. The District Court's order implements the decision of the U.S. Court of Appeals for the 11th Circuit, which ruled that the U.S FDA's approval of...
CORAL GABLES, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare...
CORAL GABLES, Fla., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare d...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...
2024-06-03 10:15:02 ET Oppenheimer analyst issues BUY recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Buy. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...